Current Insights of BRAF Inhibitors in Cancer

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Oncogenic BRAF kinase deregulates the ERK signaling pathway in a large number of human tumors. FDA-approved BRAF inhibitors for BRAFV600E/K tumors have provided impressive clinical responses extending survival of melanoma patients. However, these drugs display paradoxical activation in normal tissue with BRAFWT due to RAF transactivation and priming, acquired drug resistance, and limited clinical effectiveness in non-V600 BRAF-dependent tumors, underscoring the urgent need to develop improved BRAF inhibitors. This review provides an overview of recent structural and biochemical insights into the mechanisms of BRAF regulation by BRAF inhibitors that are linked to their clinical activity, clinical liabilities, and medicinal chemistry properties. The effectiveness and challenges of structurally diverse next generation RAF inhibitors currently in preclinical and clinical development are discussed, along with mechanistic insights for developing more effective RAF inhibitors targeting different oncogenic BRAF conformations.

Original languageEnglish (US)
Pages (from-to)5775-5793
Number of pages19
JournalJournal of Medicinal Chemistry
Volume61
Issue number14
DOIs
StatePublished - Jul 26 2018

Fingerprint

Proto-Oncogene Proteins B-raf
Neoplasms
Clinical Chemistry
Pharmaceutical Chemistry
MAP Kinase Signaling System
Drug Resistance
Transcriptional Activation
Melanoma
Survival
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Current Insights of BRAF Inhibitors in Cancer. / Agianian, Bogos; Gavathiotis, Evripidis.

In: Journal of Medicinal Chemistry, Vol. 61, No. 14, 26.07.2018, p. 5775-5793.

Research output: Contribution to journalReview article

@article{9e9ebe687bf34738af643dccab66a643,
title = "Current Insights of BRAF Inhibitors in Cancer",
abstract = "Oncogenic BRAF kinase deregulates the ERK signaling pathway in a large number of human tumors. FDA-approved BRAF inhibitors for BRAFV600E/K tumors have provided impressive clinical responses extending survival of melanoma patients. However, these drugs display paradoxical activation in normal tissue with BRAFWT due to RAF transactivation and priming, acquired drug resistance, and limited clinical effectiveness in non-V600 BRAF-dependent tumors, underscoring the urgent need to develop improved BRAF inhibitors. This review provides an overview of recent structural and biochemical insights into the mechanisms of BRAF regulation by BRAF inhibitors that are linked to their clinical activity, clinical liabilities, and medicinal chemistry properties. The effectiveness and challenges of structurally diverse next generation RAF inhibitors currently in preclinical and clinical development are discussed, along with mechanistic insights for developing more effective RAF inhibitors targeting different oncogenic BRAF conformations.",
author = "Bogos Agianian and Evripidis Gavathiotis",
year = "2018",
month = "7",
day = "26",
doi = "10.1021/acs.jmedchem.7b01306",
language = "English (US)",
volume = "61",
pages = "5775--5793",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "14",

}

TY - JOUR

T1 - Current Insights of BRAF Inhibitors in Cancer

AU - Agianian, Bogos

AU - Gavathiotis, Evripidis

PY - 2018/7/26

Y1 - 2018/7/26

N2 - Oncogenic BRAF kinase deregulates the ERK signaling pathway in a large number of human tumors. FDA-approved BRAF inhibitors for BRAFV600E/K tumors have provided impressive clinical responses extending survival of melanoma patients. However, these drugs display paradoxical activation in normal tissue with BRAFWT due to RAF transactivation and priming, acquired drug resistance, and limited clinical effectiveness in non-V600 BRAF-dependent tumors, underscoring the urgent need to develop improved BRAF inhibitors. This review provides an overview of recent structural and biochemical insights into the mechanisms of BRAF regulation by BRAF inhibitors that are linked to their clinical activity, clinical liabilities, and medicinal chemistry properties. The effectiveness and challenges of structurally diverse next generation RAF inhibitors currently in preclinical and clinical development are discussed, along with mechanistic insights for developing more effective RAF inhibitors targeting different oncogenic BRAF conformations.

AB - Oncogenic BRAF kinase deregulates the ERK signaling pathway in a large number of human tumors. FDA-approved BRAF inhibitors for BRAFV600E/K tumors have provided impressive clinical responses extending survival of melanoma patients. However, these drugs display paradoxical activation in normal tissue with BRAFWT due to RAF transactivation and priming, acquired drug resistance, and limited clinical effectiveness in non-V600 BRAF-dependent tumors, underscoring the urgent need to develop improved BRAF inhibitors. This review provides an overview of recent structural and biochemical insights into the mechanisms of BRAF regulation by BRAF inhibitors that are linked to their clinical activity, clinical liabilities, and medicinal chemistry properties. The effectiveness and challenges of structurally diverse next generation RAF inhibitors currently in preclinical and clinical development are discussed, along with mechanistic insights for developing more effective RAF inhibitors targeting different oncogenic BRAF conformations.

UR - http://www.scopus.com/inward/record.url?scp=85048865614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048865614&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.7b01306

DO - 10.1021/acs.jmedchem.7b01306

M3 - Review article

C2 - 29461827

AN - SCOPUS:85048865614

VL - 61

SP - 5775

EP - 5793

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 14

ER -